Analytical methods Selection criteria:
Considering that cores on muscle biopsy are a nonspecific finding and variations of uncertain significance are particularly common in the RYR1 gene, genetic testing in CCD should only be initiated based on a comprehensive assessment of clinical, histopathological and, increasingly, muscle MRI features at a specialist neuromuscular centre. A certain combination of features, none of them specific in isolation, is suggestive of RYR1 involvement and should prompt RYR1 mutation screening. In general, it is of note that CCD is part of clinical and histopathological spectrum of RYR1-related myopathies and in particular shows some overlap with MmD (see also Clinical Utility Gene Card: Multi-minicore Disease).
Clinical features: Most patients with RYR1-related CCD typically have mild-to-moderate axial and proximal weakness pronounced in the hip girdle. 1 Marked facial and extraocular involvement is not a typical feature. Bulbar and respiratory involvement is uncommon and, if at all present, mild. A primary cardiomyopathy is not a feature in RYR1-related CCD and suggests (a) different genetic condition(s). Histopathological features: Typical RYR1-related CCD is characterised by well-defined, single or multiple, central or eccentric cores running a significant extent along the longitudinal muscle fibre axis on muscle biopsy. 14 In cases with suggestive clinical features but less specific histopathological findings such as type 1 predominance, uniformity, 15 or cores and rods, 16, 17 muscle MRI may be more indicative of RYR1 involvement than muscle biopsy (see below). Muscle MR imaging: Muscle MR imaging in RYR1-related CCD shows a characteristic and consistent pattern of selective involvement, which may aid genetic testing and distinguish from core myopathies with different genetic backgrounds. The particular pattern of selective involvement in RYR1-related CCD is as follows: within the thigh there is selective sparing of the rectus femoris compared with the vasti, of the adductor longus compared with the adductor magnus and of the gracilis compared with the sartorius. Within the lower leg, there is prominent involvement of the peroneal group compared with the tibialis anterior, and of the soleus compared with the gastrocnemii. Although still discernible, the contrast between affected and unaffected muscles is often not as prominent in recessive compared with dominant RYR1-related CCD. [18] [19] [20] RYR1 mutation screening: Genomic sequencing of coding regions and flanking intronic sequence by conventional Sanger sequencing is currently the main strategy for RYR1 mutation screening in CCD. In future, array CGH, next generation sequencing and/or multiplex ligation-dependent probe amplification are likely to enable the additional detection of larger deletions, duplications and genomic rearrangements, 21 although the latter are likely to have a more prominent role in recessively inherited RYR1-related myopathies such as MmD 22 than typical, dominantly inherited CCD.
Analytical validation
Direct sequencing of both DNA strands is performed. Some RYR1 variants, often those associated with recessive inheritance (see also Clinical Utility Gene Card: Multi-minicore Disease), may not be detectable on genomic sequencing and cDNA analysis will be required. Any sequence variant identified on genomic DNA sequencing is confirmed on a second analysis of the index case' DNA sample. If a gross deletion or duplication is identified (using, for example, next generation sequencing), confirmation with a second technique is advisable.
The pathogenicity of variants can be assessed using commercially available mutation interpretation software or alternative approaches to interrogate online data resources. Functional studies for the assessment of RYR1 variations of uncertain significance are currently only available in selected cases on a research basis.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) The birth prevalence or population prevalence of CCD or other RYR1-related myopathies is not accurately known. A regional study in the north of England 23 estimated a frequency for CCD of 1 in 250 000. The carrier frequency for heterozygous RYR1 mutations in the Japanese population 9 is expected to be as high as 1 in 2000. The genetic incidence of the allelic MHS trait and the clinical prevalence of overt malignant hyperthermia (MH) reactions has been estimated at 1 in 3000-10 000 and 1 in 60 000-100 000, respectively, 24 but may be as high as 1 in 2000. 25 1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable for CCD. However, specific MH-related RYR1 mutations or other RYR1-related myopathies have been found to be more prevalent in certain populations. 26, 27 1.10 Diagnostic setting
Comment:
Predictive testing: In many cases, testing for RYR1 mutations does not only test for CCD but also for the MHS trait, an allelic but not consistently associated complication of mainly dominantly inherited RYR1 mutations. 24 In families where the mutation identified has been previously documented to be MHS-associated, the index case and relatives found to harbour the same change can be advised directly about their MHS risk. In families where the mutation identified has not been previously documented to be MHSassociated, the index case and relatives found to harbour the same change can be referred for appropriate testing. Risk assessment in relatives: Families with more than one pathogenic RYR1 mutation running independently in the family have been recognised. It is therefore advisable to screen the entire RYR1 gene in affected relatives with suggestive clinical and histopathological features, even if a RYR1 mutation previously identified in an affected index case has been excluded. Prenatal diagnosis: It is expected that the greater availability of RYR1 mutation screening will also increase requests for prenatal diagnosis. Prenatal diagnosis may be difficult in CCD and other RYR1-related myopathies because of not only the large number of RYR1 variations of uncertain significance but also variable clinical expressivity of pathogenic RYR1 mutations even in the same family (see also section 2.5). We would therefore only consider prenatal diagnosis in families where pathogenicity for (a) RYR1 mutation(s) identified has been clearly established and no other sequence variations of uncertain significance have been identified on complete sequencing of both parents.
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
No precise data regarding the analytical sensitivity of RYR1 testing in CCD are currently available. However, analytical sensitivity is likely to be o100% if no diagnostic test for large-scale deletions, duplications, splice mutations or genomic rearrangements has been performed. Many of these variations are not detectable on genomic sequencing and will require cDNA sequencing. However, large-scale deletions, duplications, splice mutations or genomic rearrangements are more likely to have a role in recessively inherited, RYR1-related myopathies such as certain subgroups of MmD 22 (see also Clinical Utility Gene Card for: Multi-minicore Disease). Criteria for determining the pathogenicity of an RYR1 mutation are as follows:
1. Nonsense mutation. 2. Splice-site mutations affecting canonical splice sequence or shown to alter splicing at mRNA/cDNA level. 3. Out-of-frame and in-frame deletion or insertion. 4. De novo missense mutation (with proven paternity and absence of disease in parents). 5. Missense mutation previously shown to segregate in other CCD families. 6. Missense mutation involving a highly conserved amino acid. For other missense mutations, the search for segregation in the family should be performed if possible. 7. Functional proof of pathogenecity.
Analytical specificity (proportion of negative tests if the genotype is not present)
No precise data regarding the analytical specificity of RYR1 testing in CCD are currently available. However, RYR1 sequence variations of uncertain significance are common, with only a small proportion of those having been functionally characterised to date, with an associated risk of false-positive results.
Clinical sensitivity (proportion of positive tests if the disease is present)
In general terms, clinical sensitivity is dependent on variable factors such as age at testing and a positive or negative family history. More specifically, clinical sensitivity for RYR1 mutation screening also depends on the method used for mutation screening, as for example rarely larger copy number variations or genomic rearrangements may be missed on routine sequencing, and, more importantly, the stringent application of clinical and histopathological selection criteria as outlined in Paragraph 1.6. Although a recent study in the Japanese population involving larger patient numbers indicates that RYR1 is the causative gene in more than 90% of patients with CCD, 9 there is also evidence for genetic heterogeneity accounting for the imperfect clinical sensitivity of RYR1 screening in CCD:
In a large series of 86 families with typical features of CCD, RYR1 involvement was excluded by cDNA analysis or linkage analysis in 7 families. 28 Central cores and multi-minicores as the main feature on muscle biopsy have been reported in a number of genetically distinct myopathies, often associated with clinical features unusual in the context of RYR1-related CCD such as a primary cardiomyopathy or prominent distal involvement. Dominant missense mutations in the b-myosin heavy-chain gene, MYH7, 29 may give rise to central cores on muscle biopsy with a distinct associated myopathy phenotype with or without cardiac impairment. 30 A cardiomyopathy associated with cores on muscle biopsy has also been documented in a mildly affected family harbouring dominant ACTA1 mutations 31 and severely affected siblings with homozygous truncating recessive titin mutations. 32 Central cores and multi-minicores as a secondary feature on muscle biopsy have been reported associated with mutations in the ACTA1, 33 DNM2 34 and NEB 35 genes, however, in most of these cases other findings, namely nemaline rods or centralised internal nuclei, are the most prominent histopathological feature. Combination of central cores and nemaline rods in particular may also be seen with certain RYR1 mutations. 16, 17 2.4 Clinical specificity (proportion of negative tests if the disease is not present) No precise data regarding the clinical specificity of RYR1 testing in CCD are currently available, however, clinical specificity is likely to be o100% considering the large number of sequence variations of uncertain significance identified in the RYR1 gene. In most cases, a detailed clinical assessment and muscle biopsy will have been performed before genetic testing; therefore, presence of the condition is a prerequisite for the initiation of genetic testing but also of importance for the interpretation of RYR1 variations of uncertain significance.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
Penetrance of CCD-associated RYR1 mutations is likely to be near 100% with, however, marked inter-and intrafamilial clinical variability. Cases with a CCD presentation and a RYR1 sequence variant inherited from an asymptomatic or paucisymptomatic parent have indeed been reported and are increasingly being recognised. Although other genetic modifiers cannot be excluded, this is often due to the presence of a second RYR1 variant on the background of a dominantly inherited RYR1 mutation, often associated with the MHS trait, running in the family. For example, it has been reported that offspring of asymptomatic parents harbouring a MH mutation may develop a myopathy, due to homozygosity for the MH-associated RYR1 variant in the child. 36 Along the same lines, King-Denborough syndrome, another RYR1-related myopathy with dysmorphic features, has recently been attributed to compound heterozygositiy for a dominant MH mutation running in the family and a second RYR1 variant in the child not always detected on traditional sequencing but reducing the amount of functional RyR1 protein. 37 These examples illustrate a complex inheritance pattern associated with RYR1-related disorders, with some RYR1 mutations behaving as dominants with regards to the MHS trait but as recessives with regards to congenital myopathy phenotypes. Pathogenicity can only be reliably assigned and predicted if sequencing of the entire RYR1 gene has been performed and all RYR1 variants potentially contributing to a at risk genotype have been identified.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Index case in that family had been tested: The negative clinical predictive value is likely to be o100% in RYR1-related CCD, as pedigrees with more than one disease-causing RYR1 mutation running independently in different branches of the family as well as locus heterogeneity have been recognised. In a prenatal diagnosis situation, where the possibility of additional pathogenic mutations can be ruled out (ie, by sequencing both parents), then the negative clinical predictive value is expected to be close to 100%.
Index case in that family had not been tested: When the index case in that family had not been tested, predictive testing in another family member should only be proposed when the family member fulfils the clinical and pathological criteria as outlined in Paragraph 1.6.
CLINICAL UTILITY
3.1 (Differential) diagnosis: the tested person is clinically affected (To be answered if in 1.10 'A' was marked) Genetic testing for RYR1 mutations is important in the differential diagnosis of patients with clinical features of a congenital myopathy and histopathological findings suggestive of CCD.
Can a diagnosis be made other than through a genetic test?:
Because CCD is a clinical and, most importantly, a histopathological diagnosis, a primary molecular genetic analysis is indicated only in familial cases with typical clinical features, which must include muscle weakness, and known associated RYR1 mutations. In all other cases, a comprehensive assessment comprising detailed evaluation of clinical, histopathological and, where possible, muscle MRI imaging features should be performed before genetic testing and therefore represents a prerequisite to genetic testing rather than a diagnostic alternative.
Describe the burden of alternative diagnostic methods to the patient:
Detailed clinical neuromuscular assessment, a muscle biopsy with or without muscle MRI, is required in the index case to inform the choice of genetic testing and to establish the diagnosis. A muscle biopsy is 
2 Muscle biopsy also important to obtain cDNA as some causative mutations, particularly those associated with recessive core myopathies (see also Clinical Utility Gene Card for: Multi-minicore Disease), may not be detectable on genomic sequencing. A muscle biopsy in particular is an invasive procedure and will require local or general anaesthesia but its rate of complications is usually very low. Muscle MR imaging may require sedation in young children o5 years of age. Molecular genetic analysis may replace above procedures in similarly affected relatives of index cases where the genetic diagnosis has been unequivocally established.
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged? Unknown.
Will disease management be influenced by the result of a genetic test?
3.2 Predictive setting: the tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
Yes.
If the test result is positive (please describe): Genetic confirmation of the clinicopathological diagnosis of RYR1-related CCD will help to focus multidisciplinary follow-up and management as outlined in Paragraph 3.1.4.
If the test result is negative (please describe):
Follow-up is dispensable if familial mutations in RYR1 have been excluded and no clinicopathological features of CCD are present. Follow-up should be arranged as outlined in Paragraph 3.1.4 if clinicopathological features of CCD are present but no RYR1 mutation could be identified. We personally do recommend testing also for asymptomatic parents and other relatives, both to determine the precise inheritance pattern in the family but also to advice the parents about their potential MHS risk. As the associated MHS risk has been determined only for a proportion of known RYR1 variants, we do recommend MHS precautions even if the associated MHS risk of the specific RYR1 mutation is uncertain. We also generally recommend IVCT testing in patients or asymptomatic carriers older than 16 years of age, where the associated MHS risk of the RYR1 variant identified has not been previously documented. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic
The genetic resolution of the clinicopathological diagnosis of CCD will help to focus multidisciplinary management, therapeutic interventions and follow-up as outlined below. Therapy
(please describe)
There are no specific pharmacological agents currently consistently administered in RYR1-related CCD. However, preliminary data for example on the use of salbutamol in RYR1-related myopathies 38 suggest that genetic testing in CCD may also provide the basis for rationale pharmacological therapies in the future. Prognosis The genetic result will help to focus multidisciplinary clinical follow-up and treatments, including regular assessments of neuromuscular function and monitoring for contractures, scoliosis and joint dislocations, which are frequently associated and may require orthotic or orthopaedic intervention. Exercise-induced myalgias are a common feature of some patients with RYR1-related CCD and may require medical intervention. Some individuals with RYR1-related CCD may be at an increased risk of suffering MH reactions in response to volatile anaesthetics and muscle relaxants, and genetic confirmation of the diagnosis will lead to initiation of appropriate testing and preventive measures around operative procedures. 20 Initiation of pharmacological treatments such as salbutamol may be of benefit in some individuals with RYR1-related CCD. The risk of a primary cardiomyopathy is probably higher in RYR1-negative patients with CCD and follow-up should be planned accordingly.
test is nevertheless useful for the patient or his/her relatives (please describe)?
Yes. In many cases, the genetic diagnosis contributes substantially to a diagnostic conclusion, particularly, if histopathological findings are not entirely typical. Recognising a particular congenital myopathy as RYR1-related CCD will help to anticipate future course, plan interventions and prevent potential complications. It will also end an often lengthy diagnostic process for affected individuals and their families.
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